Last reviewed · How we verify
Niflamol (NIFLUMIC ACID)
Niflamol (generic name: NIFLUMIC ACID) is a niflumic acid drug. It is currently in Phase 2 development.
Niflumic acid works by blocking potassium channels to reduce inflammation.
Niflamol is a small molecule medication. It is also known by other names, including Niflumic acid, Niflumatic acid, and Niflumatico.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
CNS / neurology attrition
-3.0pp
CNS drugs have historically high Phase 3 failure rates (notably in Alzheimer disease + major depression).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | NIFLUMIC ACID |
|---|---|
| Drug class | niflumic acid |
| Target | Chloride channel protein ClC-Ka, Chloride channel protein ClC-Kb, Potassium channel subfamily T member 2 |
| Modality | Small molecule |
| Therapeutic area | Neuroscience |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a fire station, and inflammation is like a fire. Potassium channels help control the flow of information between cells, but when they're overactive, it's like the fire alarm is going off too much. Niflumic acid helps calm down the potassium channels, reducing the inflammation and 'fire' in the body.
Approved indications
Common side effects
- Aspirin-exacerbated respiratory disease
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Niflamol CI brief — competitive landscape report
- Niflamol updates RSS · CI watch RSS
Frequently asked questions about Niflamol
What is Niflamol?
How does Niflamol work?
What is the generic name of Niflamol?
What drug class is Niflamol in?
What development phase is Niflamol in?
What are the side effects of Niflamol?
What does Niflamol target?
Related
- Drug class: All niflumic acid drugs
- Target: All drugs targeting Chloride channel protein ClC-Ka, Chloride channel protein ClC-Kb, Potassium channel subfamily T member 2
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing